Document Detail

Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial.
MedLine Citation:
PMID:  20952767     Owner:  NLM     Status:  MEDLINE    
AIMS: The GISSI-HF trial showed that n-3 polyunsaturated fatty acids (PUFA), but not rosuvastatin, reduce morbidity and mortality in patients with symptomatic heart failure (HF) of any cause. The aim of this echocardiographic substudy of GISSI-HF was to investigate the effects of n-3 PUFA and of rosuvastatin on left ventricular (LV) function in such patients.
METHODS AND RESULTS: Six hundred and eight chronic HF patients were randomized to n-3 PUFA (n=312) or placebo (n=296); a second randomization was performed to rosuvastatin (n=212) or placebo (n=207). Echocardiographic examinations were recorded at baseline and at 1, 2, and 3 years; offline analysis was performed by a core laboratory to ensure consistent quantitative analysis. Baseline LV ejection fraction (EF) was 30% (95%CI 29-31). Left ventricular ejection fraction increased with n-3 PUFA by 8.1% at 1 year, 11.1% at 2 years, and 11.5% at 3 years vs. 6.3% at 1 year, 8.2% at 2 years, and 9.9% at 3 years in the placebo group (P=0.0050). No other echocardiographic parameter changed significantly. Rosuvastatin effects were not statistically significant.
CONCLUSION: n-3 PUFA can provide a small but statistically significant advantage in terms of LV function in patients with symptomatic HF of any aetiology, already treated with recommended therapies.
Stefano Ghio; Laura Scelsi; Roberto Latini; Serge Masson; Ermanno Eleuteri; Michela Palvarini; Olga Vriz; Michele Pasotti; Marco Gorini; Roberto Marchioli; Aldo Maggioni; Luigi Tavazzi;
Related Documents :
1832347 - Abnormal diastolic left ventricular filling by pulsed doppler echocardiography in patie...
16818457 - Utility of a new left ventricular asynchrony index as a predictor of reverse remodellin...
23728227 - Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronar...
22176387 - Nonvolumetric echocardiographic indices of right ventricular systolic function: validat...
21167337 - Door-to-balloon times for patients with st-segment elevation myocardial infarction requ...
24093857 - Atrial fibrillation in myocardial infarction patients: impact on health care utilization.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-10-16
Journal Detail:
Title:  European journal of heart failure     Volume:  12     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-06-02     Revised Date:  2011-09-29    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1345-53     Citation Subset:  IM    
Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Fatty Acids, Omega-3 / pharmacology,  therapeutic use*
Fluorobenzenes / pharmacology,  therapeutic use*
Health Status Indicators
Heart Failure / drug therapy*,  pathology,  ultrasonography
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use*
Pyrimidines / pharmacology,  therapeutic use*
Stroke Volume / drug effects
Sulfonamides / pharmacology,  therapeutic use*
Treatment Outcome
Ventricular Function, Left / drug effects*
Reg. No./Substance:
0/Fatty Acids, Omega-3; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin
Erratum In:
Eur J Heart Fail. 2011 Sep;13(9):1042

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inaccuracy of radiological and ECG criteria for right ventricular outflow tract implantation of pace...
Next Document:  Influence of cardiomegaly on disordered breathing during exercise in chronic heart failure.